Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jun:248:72-83.
doi: 10.1016/j.ahj.2022.01.017. Epub 2022 Feb 9.

Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial

Affiliations
Clinical Trial

Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial

Mandeep S Sidhu et al. Am Heart J. 2022 Jun.

Abstract

Background: The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches trial demonstrated no overall difference in the composite primary endpoint and the secondary endpoints of cardiovascular (CV) death/myocardial infarction or all-cause mortality between an initial invasive or conservative strategy among participants with chronic coronary disease and moderate or severe myocardial ischemia. Detailed cause-specific death analyses have not been reported.

Methods: We compared overall and cause-specific death rates by treatment group using Cox models with adjustment for pre-specified baseline covariates. Cause of death was adjudicated by an independent Clinical Events Committee as CV, non-CV, and undetermined. We evaluated the association of risk factors and treatment strategy with cause of death.

Results: Four-year cumulative incidence rates for CV death were similar between invasive and conservative strategies (2.6% vs 3.0%; hazard ratio [HR] 0.98; 95% CI [0.70-1.38]), but non-CV death rates were higher in the invasive strategy (3.3% vs 2.1%; HR 1.45 [1.00-2.09]). Overall, 13% of deaths were attributed to undetermined causes (38/289). Fewer undetermined deaths (0.6% vs 1.3%; HR 0.48 [0.24-0.95]) and more malignancy deaths (2.0% vs 0.8%; HR 2.11 [1.23-3.60]) occurred in the invasive strategy than in the conservative strategy.

Conclusions: In International Study of Comparative Health Effectiveness with Medical and Invasive Approaches, all-cause and CV death rates were similar between treatment strategies. The observation of fewer undetermined deaths and more malignancy deaths in the invasive strategy remains unexplained. These findings should be interpreted with caution in the context of prior studies and the overall trial results.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Time to event curves for the outcome of death from any cause. The shaded region of the plot displays the half width of the confidence interval for the difference between treatment groups. Overlap of the lines and shading indicates that the 95% CI for the difference includes zero. Figure 1A: Cumulative incidence of death from any cause in the conservative strategy group and invasive strategy group. From N Engl J Med, Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease, 382:1395–1407. Copyright © (2020) Massachusetts Medical Society. Reprinted with permission. Figure 1B: Cumulative incidence of cardiovascular death in the conservative strategy group and invasive strategy group. From N Engl J Med, Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease, 382:1395–1407. Copyright © (2020) Massachusetts Medical Society. Reprinted with permission. Figure 1C: Cumulative incidence of non-cardiovascular death in the conservative strategy group and invasive strategy group. Figure 1D: Cumulative incidence of undetermined death in the conservative strategy group and invasive strategy group.
Figure 1:
Figure 1:
Time to event curves for the outcome of death from any cause. The shaded region of the plot displays the half width of the confidence interval for the difference between treatment groups. Overlap of the lines and shading indicates that the 95% CI for the difference includes zero. Figure 1A: Cumulative incidence of death from any cause in the conservative strategy group and invasive strategy group. From N Engl J Med, Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease, 382:1395–1407. Copyright © (2020) Massachusetts Medical Society. Reprinted with permission. Figure 1B: Cumulative incidence of cardiovascular death in the conservative strategy group and invasive strategy group. From N Engl J Med, Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease, 382:1395–1407. Copyright © (2020) Massachusetts Medical Society. Reprinted with permission. Figure 1C: Cumulative incidence of non-cardiovascular death in the conservative strategy group and invasive strategy group. Figure 1D: Cumulative incidence of undetermined death in the conservative strategy group and invasive strategy group.
Figure 1:
Figure 1:
Time to event curves for the outcome of death from any cause. The shaded region of the plot displays the half width of the confidence interval for the difference between treatment groups. Overlap of the lines and shading indicates that the 95% CI for the difference includes zero. Figure 1A: Cumulative incidence of death from any cause in the conservative strategy group and invasive strategy group. From N Engl J Med, Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease, 382:1395–1407. Copyright © (2020) Massachusetts Medical Society. Reprinted with permission. Figure 1B: Cumulative incidence of cardiovascular death in the conservative strategy group and invasive strategy group. From N Engl J Med, Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease, 382:1395–1407. Copyright © (2020) Massachusetts Medical Society. Reprinted with permission. Figure 1C: Cumulative incidence of non-cardiovascular death in the conservative strategy group and invasive strategy group. Figure 1D: Cumulative incidence of undetermined death in the conservative strategy group and invasive strategy group.
Figure 1:
Figure 1:
Time to event curves for the outcome of death from any cause. The shaded region of the plot displays the half width of the confidence interval for the difference between treatment groups. Overlap of the lines and shading indicates that the 95% CI for the difference includes zero. Figure 1A: Cumulative incidence of death from any cause in the conservative strategy group and invasive strategy group. From N Engl J Med, Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease, 382:1395–1407. Copyright © (2020) Massachusetts Medical Society. Reprinted with permission. Figure 1B: Cumulative incidence of cardiovascular death in the conservative strategy group and invasive strategy group. From N Engl J Med, Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease, 382:1395–1407. Copyright © (2020) Massachusetts Medical Society. Reprinted with permission. Figure 1C: Cumulative incidence of non-cardiovascular death in the conservative strategy group and invasive strategy group. Figure 1D: Cumulative incidence of undetermined death in the conservative strategy group and invasive strategy group.
Figure 2:
Figure 2:
The interaction with death type is used to assess whether a covariate’s association with death differed by cause of death.
Figure 3:
Figure 3:
Time to event curves for the cumulative incidence plot of new malignancy during the study period for the conservative strategy arm and invasive strategy arm. The gray shaded region of the plot displays the half width of the confidence interval for the difference between treatment groups. Overlap of the lines and shading indicates that the 95% CI for the difference includes zero.

Similar articles

  • Cause-Specific Mortality in Patients With Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial.
    Sidhu MS, Alexander KP, Huang Z, Mathew RO, Newman JD, O'Brien SM, Pellikka PA, Lyubarova R, Bockeria O, Briguori C, Kretov EL, Mazurek T, Orso F, Roik MF, Sajeev C, Shutov EV, Rockhold FW, Borrego D, Balter S, Stone GW, Chaitman BR, Goodman SG, Fleg JL, Reynolds HR, Maron DJ, Hochman JS, Bangalore S; ISCHEMIA-CKD Research Group. Sidhu MS, et al. JACC Cardiovasc Interv. 2023 Jan 23;16(2):209-218. doi: 10.1016/j.jcin.2022.10.062. JACC Cardiovasc Interv. 2023. PMID: 36697158 Free PMC article. Clinical Trial.
  • Survival After Invasive or Conservative Management of Stable Coronary Disease.
    Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O'Brien SM, Mavromichalis S, Chang M, Contreras A, Rosenberg Y, Kirby R, Bhargava B, Senior R, Banfield A, Goodman SG, Lopes RD, Pracoń R, López-Sendón J, Maggioni AP, Newman JD, Berger JS, Sidhu MS, White HD, Troxel AB, Harrington RA, Boden WE, Stone GW, Mark DB, Spertus JA, Maron DJ; ISCHEMIA-EXTEND Research Group. Hochman JS, et al. Circulation. 2023 Jan 3;147(1):8-19. doi: 10.1161/CIRCULATIONAHA.122.062714. Epub 2022 Nov 6. Circulation. 2023. PMID: 36335918 Free PMC article. Clinical Trial.
  • Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons.
    Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, Boden WE, Lopes RD, Demkow M, Piero Perna G, Riezebos RK, McFalls EO, Banerjee S, Bagai A, Gosselin G, O'Brien SM, Rockhold FW, Waters DD, Thygesen KA, Stone GW, White HD, Maron DJ, Hochman JS; ISCHEMIA Research Group. Chaitman BR, et al. Circulation. 2021 Feb 23;143(8):790-804. doi: 10.1161/CIRCULATIONAHA.120.047987. Epub 2020 Dec 3. Circulation. 2021. PMID: 33267610 Free PMC article. Clinical Trial.
  • International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design.
    ISCHEMIA Trial Research Group; Maron DJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangalore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB Jr, Williams DO, Harrington RA, Rosenberg Y. ISCHEMIA Trial Research Group, et al. Am Heart J. 2018 Jul;201:124-135. doi: 10.1016/j.ahj.2018.04.011. Epub 2018 Apr 21. Am Heart J. 2018. PMID: 29778671 Free PMC article. Review.
  • Initial Invasive or Conservative Strategy for Stable Coronary Disease.
    Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y; ISCHEMIA Research Group. Maron DJ, et al. N Engl J Med. 2020 Apr 9;382(15):1395-1407. doi: 10.1056/NEJMoa1915922. Epub 2020 Mar 30. N Engl J Med. 2020. PMID: 32227755 Free PMC article. Clinical Trial.

Cited by

References

    1. Virani S, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics – 2020 Update: A report from AHA. Circulation. 2020;141: e139–e596 - PubMed
    1. Mensah GA, Wei GS, Sorlie PD, et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ Res 2017;120(2): 366–380. - PMC - PubMed
    1. Moran AE, Forouzanfar MH, Roth GA, et al. Temporal Trends in Ischemic Heart Disease Death in 21 World Regions, 1980 to 2010. Circulation, 2014;129(14): 1483–1492. - PMC - PubMed
    1. Ford ES, Ajani UA, Croft JB et al.; Explaining the decrease in US Deaths from Coronary Disease, 1980–2000. N Engl J Med. 2007; 356: 2388–2398. - PubMed
    1. Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Eng J Med. 2020; 1395–1407. - PMC - PubMed

Publication types